Wells Fargo analyst Jim Birchenough maintained a Buy rating on Immunomedics (NASDAQ: IMMU) yesterday. The company’s shares closed yesterday at $21.35.
According to TipRanks.com, Birchenough is a 5-star analyst with an average return of 21.5% and a 46.7% success rate. Birchenough covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Aeglea Biotherapeutics Inc, and Five Prime Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunomedics with a $38.50 average price target.
See today’s analyst top recommended stocks >>
Based on Immunomedics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $117 million. In comparison, last year the company had a GAAP net loss of $119 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immunomedics, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. It operates through the United States, and Europe geographical segments.
